Skip to content
DraconiticResearch
Search Sources API
190,335 studies31 sourcesUpdated 58 min ago
Peer-reviewedCC BY-NC-ND 4.0In Vivo

Usefulness of Texture Analysis in 11C-Choline PET/CT for Patients With Prostate Cancer

  • TATSUYA TSUCHITANI1
  • KAZUHIRO KITAJIMA2
  • YOSHIYUKI TAKAHASHI1
  • SHINGO YAMAMOTO3
  • KOICHIRO YAMAKADO2
  1. 1Department of Radiological Technology, Hyogo Medical University Hospital, Hyogo, Japan
  2. 2Department of Radiology, Hyogo Medical University, Hyogo, Japan
  3. 3Department of Urology, Hyogo Medical University, Hyogo, Japan
Read full textPDFDOICite

Abstract

Background/Aim: Texture analysis provides quantitative evaluation of intratumoral heterogeneity of radiopharmaceutical uptake. ComBat harmonization, which reduces batch effects, has been applied in several 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) texture analysis studies. In addition, 11C-Choline PET/CT has been reported to be useful for evaluating urological tumors, including prostate cancer. This study investigated whether texture parameters derived from 11C-Choline PET/CT are associated with prostate cancer aggressiveness.

Patients and Methods: A retrospective analysis was performed in 18 patients diagnosed with prostate cancer who underwent 11C-Choline PET/CT examinations. Six texture features were evaluated: entropy, homogeneity, dissimilarity, intensity variability (IV), size-zone variability (SZV) and zone percentage (ZP). Correlation coefficients between the six texture parameters and Gleason score were calculated.

Results: Among the evaluated texture parameters, SZV showed the strongest correlation with Gleason score (ρ=0.45), followed by IV (ρ=0.44), entropy (ρ=0.08), homogeneity (ρ=0.04), ZP (ρ=0.03), and dissimilarity (ρ=-0.02).

Conclusion: SZV and IV derived from 11C-Choline PET/CT showed correlations with Gleason score and warrant further investigation as potential imaging biomarkers of prostate cancer aggressiveness.

Related

  1. TexTNet: a texture-guided hierarchical architecture for prostate cancer Gleason segmentation in whole slide images
    Muhammad Arshad, Wang Chengliang, Muhammad Wajeeh Us Sima +3
    Frontiers in medicinePeer-reviewedCC BYFull textGeneral medicineEurope PMCPMCEurope PMC
  2. Development and Initial Validation of a Statistical Image Analysis Framework for Quantitative Bone SPECT/CT in Patients with Prostate Cancer
    Kenta Miwa, Noriaki Miyaji, Tensho Yamao +3
    Diagnostics (Basel, Switzerland)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  3. Skin‐Related Adverse Events in Patients Treated With Apalutamide Versus Enzalutamide for Prostate Cancer: A Japanese Real‐World Database Study (A Retrospective Cohort Study)
    Akihito Hashizume, Takashi Kawahara, Masanobu Yamazaki +6
    Health science reportsPeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  4. Real‐World Overall Survival With Abiraterone Acetate and Enzalutamide in Patients With Chemotherapy‐Naïve Metastatic Castration‐Resistant Prostate Cancer From the Flatiron Electronic Health Records Database
    Daniel J. George, Jasmina I. Ivanova, Maëlys Touya +6
    Cancer medicinePeer-reviewedCC BY-NC-NDFull textGeneral medicineEurope PMC
  5. Cost-effectiveness of adding enzalutamide vs standard non-steroidal antiandrogen drugs for patients with metastatic hormone-sensitive prostate cancer undergoing standard first-line therapy: a within-trial, secondary end-point analysis of the ENZAMET phase 3, international randomized trial (ANZUP 1304)
    Chi Kin Law, Martin R. Stockler, Andrew J. Martin +3
    EClinicalMedicinePeer-reviewedCC BYFull textGeneral medicineEurope PMCCrossref

Cite

BibTeXRIS
BibTeX
@article{tsuchitani2026usefulness,
  title = {{Usefulness of Texture Analysis in 11C-Choline PET/CT for Patients With Prostate Cancer}},
  author = {TATSUYA TSUCHITANI and KAZUHIRO KITAJIMA and YOSHIYUKI TAKAHASHI and SHINGO YAMAMOTO and KOICHIRO YAMAKADO},
  journal = {In Vivo},
  year = {2026},
  month = oct,
  doi = {10.21873/invivo.14523},
  url = {https://doi.org/10.21873/invivo.14523},
  note = {CC BY-NC-ND 4.0},
}
RIS
TY  - JOUR
TI  - Usefulness of Texture Analysis in 11C-Choline PET/CT for Patients With Prostate Cancer
AU  - TATSUYA TSUCHITANI
AU  - KAZUHIRO KITAJIMA
AU  - YOSHIYUKI TAKAHASHI
AU  - SHINGO YAMAMOTO
AU  - KOICHIRO YAMAKADO
PY  - 2026
DA  - 2026/10/29
JO  - In Vivo
DO  - 10.21873/invivo.14523
UR  - https://doi.org/10.21873/invivo.14523
AB  - Background/Aim: Texture analysis provides quantitative evaluation of intratumoral heterogeneity of radiopharmaceutical uptake. ComBat harmonization, which reduces batch effects, has been applied in several 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) texture analysis studies. In addition, 11C-Choline PET/CT has been reported to be useful for evaluating urological tumors, including prostate cancer. This study investigated whether texture parameters derived from 11C-Choline PET/CT are associated with prostate cancer aggressiveness.  Patients and Methods: A retrospective analysis was performed in 18 patients diagnosed with prostate cancer who underwent 11C-Choline PET/CT examinations. Six texture features were evaluated: entropy, homogeneity, dissimilarity, intensity variability (IV), size-zone variability (SZV) and zone percentage (ZP). Correlation coefficients between the six texture parameters and Gleason score were calculated.  Results: Among the evaluated texture parameters, SZV showed the strongest correlation with Gleason score (ρ=0.45), followed by IV (ρ=0.44), entropy (ρ=0.08), homogeneity (ρ=0.04), ZP (ρ=0.03), and dissimilarity (ρ=-0.02).  Conclusion: SZV and IV derived from 11C-Choline PET/CT showed correlations with Gleason score and warrant further investigation as potential imaging biomarkers of prostate cancer aggressiveness.
SN  - 0258-851X
SN  - 1791-7549
ER  -